456 related articles for article (PubMed ID: 30094623)
1. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
Sikavi C; Najarian L; Saab S
Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
3. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
5. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Patel SV; Jayaweera DT; Althoff KN; Eron JJ; Radtchenko J; Mills A; Moyle G; Santiago S; Sax PE; Gillman J; Mounzer K; Elion RA; Huhn GD
PLoS One; 2020; 15(2):e0228847. PubMed ID: 32053682
[TBL] [Abstract][Full Text] [Related]
6. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
7. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
Roberson JL; Lagasca AM; Kan VL
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
[TBL] [Abstract][Full Text] [Related]
9. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
[TBL] [Abstract][Full Text] [Related]
10. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Falade-Nwulia O; Suarez-Cuervo C; Nelson DR; Fried MW; Segal JB; Sulkowski MS
Ann Intern Med; 2017 May; 166(9):637-648. PubMed ID: 28319996
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
12. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal.
Kc S; Murphy H; Dixit S; Rai A; Pradhan B; Lagrange-Xelot M; Karki N; Dureault A; Karmacharya U; Panthi S; Tulachan N; Kc P; Kc A; Rajbhandari R; Trotter AB; Gölz J; Pradat P; Trépo C; Creac'H P
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008931. PubMed ID: 33326423
[TBL] [Abstract][Full Text] [Related]
14. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
15. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
16. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
[TBL] [Abstract][Full Text] [Related]
17. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
Shafran SD
Clin Infect Dis; 2015 Oct; 61(7):1127-34. PubMed ID: 26060286
[TBL] [Abstract][Full Text] [Related]
18. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
[TBL] [Abstract][Full Text] [Related]
19. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]